Company Interview / Australia’s biotech bright spots

Key Points:

ASX (ASX:ASX) faces criticism for governance failures, project mismanagement, and poor confidence in turnaround plansGrowing competition from Cboe and an ASIC report put further pressure on ASX leadershipJennings highlights recent gains in a basket of biotech stocks, including 4DMedical (ASX:4DX) and Neuren Pharmaceuticals (ASX:NEU)Revenue-producing biotechs with commercialisation catalysts are favoured over those purely reliant on trial outcomes

Henry Jennings from Marcus Today expresses scepticism toward the recent initiatives by ASX (ASX:ASX), following governance and capital reforms mandated by the corporate regulator. Jennings points to the cutting of its dividend payout ratio as paying for past missteps, referencing issues such as the failed CHESS replacement project and recent outages. Jennings sees ongoing challenges and lack of confidence in the management strategy, suggesting that change at the top may be needed to restore integrity and investor faith given competing pressures from rivals like Cboe and a damning report from ASIC.

Turning to the biotechnology sector, Jennings outlines Australia's strength in this space, highlighting major names such as CSL (ASX:CSL), Cochlear (ASX:COH), ResMed (ASX:RMD), Telix Pharmaceuticals (ASX:TLX), and Pro Medicus (ASX:PME). A "biotech basket" assembled by Jennings in August, including Dimerix (ASX:DXB), Mesoblast (ASX:MSB), Neuren Pharmaceuticals (ASX:NEU), and 4DMedical (ASX:4DX), has doubled in value, with 4DMedical benefiting from regulatory successes and a partnership with Philips, and Neuren's drug gaining additional approvals.

Jennings considers timing crucial in the biotech industry, identifying companies like Neuren and Dimerix (ASX:DXB) as compelling due to commercialisation milestones and revenues rather than binary drug trial outcomes.